Safety
fatigue, anemia
ADVERSE EVENT, ANEMIA
All 26 (100%) patients experienced treatment-related AEs of any grade. The most frequent AEs were anemia (57.7%), increased alkaline phosphatase (34.6%), and fatigue (30.8%) (Treatment-Related Adverse Events in Total Treated Patients (n = 26).